Buprenorphine 101 for Community Pharmacists: Case Studies to Inform Collaboration

Description

Buprenorphine is an evidence-based therapy used in medication-assisted treatment (MAT) for opioid use disorder (OUD).  Many barriers exist to expanding patient access to buprenorphine, including communication among practitioners, stigma, coverage, and awareness. This session, conducted in collaboration with the American Society of Addiction Medicine, will pair a physician specialist with a pharmacist to provide an overview of buprenorphine for MAT and apply those learnings to case studies where the patient has multiple red flags and the pharmacist must decide what to do next. 

Pharmacist Learning Objectives

At the completion of this application-based activity, participants will be able to: 

  1. Discuss the clinical approach to using buprenorphine for MAT.
  2. Explain the differences in red flags for opioids for pain management vs. buprenorphine for medication-assisted treatment.
  3. Discuss different communication strategies that should and should not be used when a patient’s buprenorphine prescriptions raises “red flags” or safety concerns.  
  4. Identify practices prescribers and pharmacists can take to proactively maintain patient access to MAT.
 

Joint Providership

Cosponsored by American Society of Addiction Medicine.

 
 
Speakers:
Dan
Dan Hein, BS, Pharm
Area Healthcare Supervisor
Walgreens
 
Shawn
Shawn Ryan,
Brightview Health
 
Learning Level: Level 1
Track: Community-Based Pharmacy Practice, Pharmacist Clinical Patient Care Services
Session Time Slot(s): 
Date: 
Friday, March 20
Time: 
10:30 AM - 11:30 AM
Room: 
Gaylord National - National Harbor 12-13
ACPE Pharmacist: 0202-0000-20-104-L01-P
CEUs Pharmacist: 0.1
Activity Type:
Application-based